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Enterovirus 71 Vaccine: When Will it be Available?
Mei-Liang Huang,1 Mei-Shang Ho,2 Min-Shi Lee1*
Enterovirus 71 (EV71) is a positive-sense RNA virus
that belongs to the enterovirus genus in the family
Picornaviridae along with other important human
pathogens, such as polioviruses and rhinoviruses.
EV71 was first isolated in l969 in the United States
from a child with neurological disease, but a recent
retrospective study suggested that EV71 was cir-
culating in the Netherlands as early as 1963.1 To
date, there is only one serotype of EV71 as mea-
sured by hyperimmune animal antiserum. Phy-
logenetically, EV71 can be classified into three
genogroups (A, B and C) and 11 genotypes (A,
B1–B5, and C1–C5) by analyzing the most vari-
able capsid protein sequences (VP1).1 From an
evolutionary prospective, a recent analysis of 628
EV71 VP1 sequences estimated that EV71 emerged
in the human population at approximately 1941.2
Recombination, which is a common occurrence
among enteroviruses, is a likely explanation for
the emergence of EV71, but it would require full
genomic analysis of EV71 to prove such an evolu-
tionary concept.
According to a clinical observation of children
acquiring EV71 infection during the 1998 outbreak
in Taiwan, severe EV71 infection progresses through
four stages: self-limited hand-foot-mouth disease/
herpangina (stage 1), encephalitis or myelitis
(stage 2), cardiopulmonary failure (stage 3), and
convalescence (stage 4). Young children under 
4 years pose a higher risk for severe infections, but
the underlying cause for the varied clinical spec-
trum is not clear.3 While cardiovascular collapse is
a terminal event of fatal EV71 infection, the virus is
not found in the heart or lung, but only in the
nervous system, suggesting that cardiopulmonary
collapse is a neurogenic event.3 Although it is con-
tinuously circulating in most countries, EV71 has
caused several outbreaks sporadically in the 1970s,
i.e. 1975 in Bulgaria and 1978 in Hungary. How-
ever, in the past decade, EV71 has appeared to cause
large outbreaks of neurological infection in several
Asian countries with increasing frequency, i.e.
1997 in Malaysia, 1998 in Taiwan, and 2008 in
China and multiple Asian countries.3,4 While the
reasons for the underlying cause of these outbreaks
remain unclear, developing an effective vaccine is
perceived as the top priority among the control
measures of EV71 in the Asian Pacific region.
Based on historical experiences with inacti-
vated poliovirus vaccines (IPV), inactivated EV71
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whole virus vaccines have been perceived as fea-
sible following the regulatory pathway of IPV.
After the Bulgaria epidemic in 1975, an inactivated
EV71 whole virus vaccine candidate was produced
in Moscow using a similar manufacturing process
as that of IPV and it was evaluated in Bulgaria 
in 1976. This EV71 vaccine candidate was well
tolerated and immunogenic in children 1–4
years of age.4 Because there were no further out-
breaks of EV71, the Bulgaria vaccine candidate
was not further evaluated for its clinical efficacy,
and no potency assay to quantify vaccine anti-
gens has been developed. Therefore, the inacti-
vated EV71 vaccine is the most likely candidate
to be launched, and phase I clinical trials are
being conducted in both China and Taiwan. To
ensure the road to success of developing EV71
vaccines to effectively control EV71 infection in
Asian countries, several scientific issues need to
be clarified to reduce the risk of product attrition
at the late stage of vaccine development during
the clinical trial stage.
First, there are several antigenic formats during
production of IPV and these different antigenic
formats show a varied capacity for inducing neu-
tralizing antibody responses. Therefore, under the
coordination of the World Health Organization,
tremendous effort has been made to establish
reference reagents based on the one specific neu-
tralizing antigen for use in establishing assays to
ensure the consistent potency of IPV.5 Moreover,
international collaborations on harmonization of
potency assays of IPV are critical for the increasing
supply of IPV produced by different manufactur-
ers.6 Therefore, regulatory authorities in Asian
countries where EV71 vaccine development pro-
grams exist would benefit from having an inter-
national network to establish an international
reference reagent for use in potency assays of EV71
vaccines. Second, epidemiological data related to
age-specific disease burden are critical for design-
ing vaccine efficacy trials and formulating vacci-
nation policy. Infants are among the high-risk
groups of severe EV71 infection and would be
the priority target population for EV71 vaccines.
To speed up the licensure of EV71 vaccines for
young infants, a multi-nation randomized con-
trolled efficacy trial is required to prove clinical
protection in this age group. However, many Asian
countries do not currently have an enterovirus
surveillance system and have no EV71 epidemio-
logical data. It is anticipated that the use of EV71
vaccine would be hampered in countries without
epidemiological data. In the limited number of
Asian countries with an enterovirus surveillance
system, case definitions and methods of laboratory
diagnosis vary country by country. Therefore, har-
monization of enterovirus surveillance would pro-
vide a better understanding of the disease burden
of EV71 in this region, help the conduct of multi-
nation randomized controlled efficacy trials, and
assist in the formulation of EV71 vaccination pol-
icy in these countries. Third, post-market study
would be of paramount importance as recent vi-
rological surveillance suggested that EV71 might
evolve with time, similar to that of influenza virus
but at a slower rate. Recent human studies con-
ducted in Taiwan detected antigenic variations
among different EV71 genogroups.7–9 Further-
more, genogroup A viruses, which have disap-
peared for almost 40 years and possess different
antigenicity from the circulating genogroups B
and C viruses, reemerged in 2008 in China.10
Moreover, EV71 has tended to evolve quickly 
in the past 20 years.3 Longitudinal studies are
warranted to clarify the clinical and epidemio-
logical significance of the antigenic and genetic
variations.
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